Biotech RadarJobs updated

COMPANY

ProMIS Neurosciences

HQ: Toronto, Ontario, Canada source · promisneurosciences.com ↗ · Canada

Clinical Phase 1

Keywords: neurology early alzheimer's disease antibody Early Onset Alzheimer Disease PMN310

Location: Toronto, Ontario, Canada · source · Aug 13, 2026

Profile checked Oct 10, 2026

$102.4MRaised (2 yrs)2Trials (company is sponsor)

Timeline

  1. Raise Private placement: $75M (total, as published), announced Jan 30, 2026. Source: SEC filing. source ↗
  2. Raise Private placement: $3M (total, as published), announced Jul 28, 2025. Source: company release on GlobeNewswire. source ↗
  3. Raise Private placement: $12M (total, as published), announced Jul 28, 2025. Source: SEC filing. source ↗
  4. Raise Follow-on offering — Registered direct: $800,000 (total, as published), announced Jul 24, 2025. Source: SEC filing. source ↗
  5. Raise Private placement: $9.2M (total, as published), announced Jul 22, 2025. Source: SEC filing. source ↗
  6. Raise Private placement: $2.4M (total, as published), announced Jul 22, 2025. Source: company release on GlobeNewswire. source ↗
  7. Trial start Phase 1: PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) source ↗
  8. Trial start 1: A Phase 1a Study of PMN310 In Healthy Volunteers source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $102.4M. Last 2 years.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT06750432PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)Phase 1Active, not recruitingDec 13, 20242026-12 (estimated)
NCT06105528A Phase 1a Study of PMN310 In Healthy Volunteers1CompletedNov 18, 2023Jul 31, 2024 (actual)
Feedback